---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-029207"
form_type: "8-K"
ticker: "CTMX"
cik: "0001501989"
company_name: "CytomX Therapeutics, Inc."
filed_at: "2024-03-11T23:59:59+00:00"
generated_at: "2026-06-04T23:46:33.451612+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CytomX FY2023 revenue $101.2M, operating expenses down 30%; BMS discontinues 986288, CX-904 data H2 2024

## Summary
- FY2023 revenue $101.2M (up from $53.2M in 2022); operating expenses $107.7M (down from $154.5M).
- Cash $174.5M at Dec 31, 2023 vs $193.7M a year earlier; includes $30M from July 2023 BVF financing.
- BMS notified CytomX it will not continue BMS-986288 beyond current Phase 2; research collaboration with multiple TCE programs continues.
- CX-904 EGFRxCD3 Phase 1a data expected H2 2024; CX-2051 and CX-801 Phase 1 starts H1 2024 after IND clearance.

## SEC filing metadata
- accession: 0000950170-24-029207
- form_type: 8-K
- ticker: CTMX
- cik: 0001501989
- company_name: CytomX Therapeutics, Inc.
- filed_at: 2024-03-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501989/000095017024029207/0000950170-24-029207-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501989/000095017024029207/ctmx-20240311.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-029207
- JSON: https://secwatch.observer/filing/0000950170-24-029207.json
- Plain text: https://secwatch.observer/filing/0000950170-24-029207.txt

## Key facts
- Earnings Releases
  CytomX Therapeutics, Inc. reported financial results for the year ended December 31, 2023.
  - Period: the year ended December 31, 2023
  - Result: reported results
  source text: On March 11, 2024, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release reporting its financial results for the year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501989/000095017024029207/0000950170-24-029207-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.